15-80168052-G-A
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000137.4(FAH):c.456G>A(p.Trp152Ter) variant causes a stop gained, splice region change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000753 in 1,461,362 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000137.4 stop_gained, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FAH | NM_000137.4 | c.456G>A | p.Trp152Ter | stop_gained, splice_region_variant | 6/14 | ENST00000561421.6 | NP_000128.1 | |
FAH | NM_001374377.1 | c.456G>A | p.Trp152Ter | stop_gained, splice_region_variant | 7/15 | NP_001361306.1 | ||
FAH | NM_001374380.1 | c.456G>A | p.Trp152Ter | stop_gained, splice_region_variant | 7/15 | NP_001361309.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FAH | ENST00000561421.6 | c.456G>A | p.Trp152Ter | stop_gained, splice_region_variant | 6/14 | 1 | NM_000137.4 | ENSP00000453347 | P1 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD3 exomes AF: 0.0000119 AC: 3AN: 251472Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135908
GnomAD4 exome AF: 0.00000753 AC: 11AN: 1461362Hom.: 0 Cov.: 31 AF XY: 0.00000550 AC XY: 4AN XY: 727048
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Tyrosinemia type I Pathogenic:4
Likely pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Sep 28, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jul 31, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 31, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 16, 2024 | This sequence change creates a premature translational stop signal (p.Trp152*) in the FAH gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in FAH are known to be pathogenic (PMID: 9101289, 9633815). This variant is present in population databases (rs370686447, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with FAH-related conditions. ClinVar contains an entry for this variant (Variation ID: 92445). For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 22, 2018 | The W152X variant in the FAH gene has been reported previously in the compound heterozygous state in an individual with persistent diarrhea, hepatomegaly, ascites, elevated serum alpha-fetoprotein and tyrosine levels and elevated succinylacetone in urine. This was consistent with a diagnosis of tyrosinemia type 1 in this patient, his sister was also previously diagnosed with tyrosinemia type 1 (Dou et al., 2013). This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The W152X variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016). We interpret W152X as a pathogenic variant. - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jun 26, 2013 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at